SGMT Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Sagimet Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.52 |
| 52 Week High | US$20.71 |
| 52 Week Low | US$2.39 |
| Beta | 0 |
| 11 Month Change | -18.85% |
| 3 Month Change | 55.33% |
| 1 Year Change | 22.83% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.66% |
Recent News & Updates
Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Recent updates
Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 31Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Apr 26Sagimet: Additional Upside Possible After Latest NASH Data Release
Jan 24Shareholder Returns
| SGMT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -24.9% | -6.5% | -1.0% |
| 1Y | 22.8% | 14.6% | 30.3% |
Return vs Industry: SGMT exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: SGMT underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| SGMT volatility | |
|---|---|
| SGMT Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SGMT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SGMT's weekly volatility has decreased from 30% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 9 | Dave Happel | www.sagimet.com |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs.
Sagimet Biosciences Inc. Fundamentals Summary
| SGMT fundamental statistics | |
|---|---|
| Market cap | US$140.74m |
| Earnings (TTM) | -US$37.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs SGMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGMT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.52m |
| Earnings | -US$37.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SGMT perform over the long term?
See historical performance and comparison